SCHEMBL7140145

SCHEMBL7140145

COc1ccc(CS[C@@H]2C[C@@H](CCC(=O)O)N(S(C)(=O)=O)C2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
PTGFR P43088 1/20 0.38
ALDH1A1 P00352 3/20 0.37
HPGD P15428 1/20 0.37
FFAR1 O14842 2/20 0.37
MMP1 P03956 3/20 0.36
MMP3 P08254 3/20 0.36
MMP9 P14780 3/20 0.36
MMP13 P45452 3/20 0.36
MMP2 P08253 2/20 0.36
KMT2A Q03164 2/20 0.35
KDM4E B2RXH2 1/20 0.35
HTRA1 Q92743 1/20 0.35
MMP7 P09237 1/20 0.35
DPP4 P27487 1/20 0.35
DPP7 Q9UHL4 1/20 0.35
POLB P06746 1/20 0.34
MAPT P10636 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7140147 1.00 HTT (0.38) HTTNPSR1PTGFRALDH1A1HPGD
SCHEMBL7136555 0.92 ALDH1A1 (0.37) HTTALDH1A1HPGDMMP1MMP3
SCHEMBL7136556 0.92 ALDH1A1 (0.37) HTTALDH1A1HPGDMMP1MMP3
SCHEMBL5410379 0.88 HTRA1 (0.34) HTTALDH1A1HPGDMMP1MMP3
SCHEMBL5410375 0.88 HTRA1 (0.34) HTTALDH1A1HPGDMMP1MMP3
SCHEMBL5405046 0.87 SIGMAR1 (0.38) ALDH1A1HPGDMMP1MMP3MMP9
SCHEMBL5405049 0.87 SIGMAR1 (0.38) ALDH1A1HPGDMMP1MMP3MMP9
SCHEMBL5409672 0.86 RAB9A (0.40)
SCHEMBL5409681 0.86 RAB9A (0.40)
SCHEMBL7144857 0.84 LMNA (0.47) HTTALDH1A1MMP1MMP3MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1303485-A1 PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME F. HOFFMANN-LA ROCHE AG (CH) 2003-04-23 EP disclosed
US-6541638-B2 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction HOFFMAN-LA ROCHE INC. 2003-04-01 US disclosed
US-20020049243-A1 Pyrrolidine derivatives HOFFMANN-LA ROCHE INC. 2002-04-25 US disclosed
WO-2002006222-A1 PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049243-A1 Pyrrolidine derivatives PREP, PEPD, DNPEP HTT 2147/4885NPSR1 979/4885PTGFR 457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.